Treatment of venous thromboembolism in cancer patients

Thrombosis Research

Volumn 102, Issue 6, 2001, Pages

  Lee, Agnes Y Y ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Anticoagulants; Central venous catheter; Heparin; Low molecular weight heparin; Neoplasm; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; COUMARIN DERIVATIVE; DANAPAROID; FIBRINOLYTIC AGENT; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NAPSAGATRAN; PENTASACCHARIDE; RECOMBINANT HIRUDIN; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOT LYSIS; CANCER; CANCER PATIENT; CENTRAL VENOUS CATHETER; COMORBIDITY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; INFERIOR CAVA VEIN; LONG TERM CARE; LUNG EMBOLISM; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT FAILURE;

EID: 0035875768     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(01)00236-5     Document Type: Article

References (101)

1. The diagnosis and treatment of thrombosis in the cancer patient
2. Diagnosis and treatment of cancer-related thrombosis
3. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
4. Low molecular weight heparin in the treatment of patients with venous thromboembolism
5. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
6. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
7. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
8. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis
9. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
10. Establishing a therapeutic range for heparin therapy
11. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis
12. Recurrent venous thrombosis and heparin therapy: An evaluation of the importance of early activated partial thromboplastin times
13. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin
14. Antithrombotic therapy for venous thromboembolic disease
15. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
16. Low molecular weight heparins
17. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis
18. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis
19. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs. intravenous heparin. An economic perspective
20. Low molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
21. Treatment of deep venous thrombosis with low molecular weight heparins. A meta-analysis
22. Comparison of efficacy and safety of low-molecular-weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: A meta-analysis
23. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: A meta-analysis of randomized, controlled trials
24. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency
25. A histomorphometric comparison of the effects of heparin and low molecular weight heparin on cancellous bone in rats
26. The effects of low molecular weight and standard heparin on calcium loss from fetal rate calvaria
27. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin
28. Heparin and angiogenesis: A low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically
29. Angiogenesis inhibition and tumour regression caused by heparin or heparin fragment in the presence of cortisone
30. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range
31. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy
32. Antithrombotic strategies in patients with cancer
33. The long term clinical course of acute deep venous thrombosis
34. Efficacy and safety of oral anticoagulation in patients with cancer
35. The efficacy and safety of oral anticoagulation in patients with cancer
36. Low-molecular-weight heparin in the management of Trousseau's syndrome
37. Trousseau's syndrome
38. Safety of low-molecular-weight heparin in pregnancy: A systematic review
39. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk
40. Use of low molecular weight heparin in pregnancy
41. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis
42. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: A randomized trial
43. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis
44. Complications and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy
45. Venous thromboembolism prophylaxis in gynecologic oncology: A prospective controlled trial of low-dose heparin
46. Safety and efficacy of long-term oral anticoagulation in cancer patients
47. Predictors of recurrence after deep vein thrombosis and pulmonary embolism. A population-based cohort study
48. Recurrent venous thromboembolism after deep vein thrombosis incidence and risk factors
49. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis
50. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis
51. Inferior vena caval filters: A review of a 26-year single-centre clinical experience
52. LGM (Vena Tech) vena caval filter: Experience at a single institution
53. Hemorrhagic complications of anticoagulant treatment
54. Risk factors for bleeding during treatment of acute venous thromboembolism
55. Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota
56. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy
57. Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors
58. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism
59. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors
60. Therapy of venous thromboembolism in patients with brain metastases
61. Treatment of thromboembolic complications in patients with brain tumors
62. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
63. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
64. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism
65. Inferior vena cava filters in cancer patients: Indications and outcomes
66. Thrombolytic therapy of pulmonary embolism: A comprehensive review of current evidence
67. Thrombolytic therapy for venous thromboembolism
68. Thrombolytic therapy for pulmonary embolism: Frequency of intracranial hemorrhage and associated risk factors
69. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism
70. Contemporary pulmonary embolism thrombolysis
71. Comparison of alteplase versus heparin for resolution of major pulmonary embolism
72. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: Immediate clinical and hemodynamic outcome and one-year follow-up
73. Streptokinase therapy for deep vein thrombosis: A comprehensive review of the English literature
74. Superior vena cava syndrome: Treatment with catheter-directed thrombolysis and endovascular stent placement
75. Superior vena cava syndrome: Current concepts of management
76. Thrombotic complication of central venous catheters in cancer patients
77. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: A double-blinded randomized trial
78. Obstructed central venous catheters: Restoring function with a 12-hour infusion of low dose urokinase
79. The relationship between the thrombotic and infectious complications of central venous catheters
80. Upper extremity deep vein thrombosis: Risk factors. Diagnosis and complications
81. Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients
82. Groshong catheter-associated subclavian venous thrombosis
83. Thrombosis: The major Hickman catheter complication in patients with solid tumor
84. Direct thrombin inhibitors
85. New antithrombotic agents
86. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393
87. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement
88. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: A multicentre prospective dose-ranging randomized trial
89. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery
90. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis: Results of the European multicentre ADVENT trial
91. Intravenous treatment of acute deep vein thrombosis (DVT) with melagatran, a synthetic low molecular weight thrombin inhibitor
92. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT
93. Subcutaneous and oral direct thrombin inhibitors for prophylaxis of deep venous thrombosis and pulmonary embolism after total hip and knee replacement
94. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism: A randomized controlled trial
95. A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement: The Danaparoid Hip Arthroplasty Investigators Group
96. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide
97. A dose-response study of the factor VIIa/tissue factor inhibitor rNAPc2 in the prevention of postoperative venous thrombosis in patients undergoing total knee arthroplasty
98. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
99. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia
100. Argatroban approved for heparin-induced thrombocytopenia
101. Orgaran (org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomized, multicentre comparison